Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report
- 31 March 2013
- journal article
- research article
- Published by Hindawi Limited in Journal of Clinical Pharmacy & Therapeutics
- Vol. 38 (2), 162-164
- https://doi.org/10.1111/jcpt.12018
Abstract
What is known and Objective: Cannabis withdrawal in heavy users is commonly followed by increased anxiety, insomnia, loss of appetite, migraine, irritability, restlessness and other physical and psychological signs. Tolerance to cannabis and cannabis withdrawal symptoms are believed to be the result of the desensitization of CB1 receptors by THC. Case summary: This report describes the case of a 19-year-old woman with cannabis withdrawal syndrome treated with cannabidiol (CBD) for 10 days. Daily symptom assessments demonstrated the absence of significant withdrawal, anxiety and dissociative symptoms during the treatment. What is new and Conclusion: CBD can be effective for the treatment of cannabis withdrawal syndrome.This publication has 32 references indexed in Scilit:
- Pharmacotherapy for Cannabis Dependence: How Close Are We?CNS Drugs, 2009
- Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptorAddiction Biology, 2008
- Marijuana Dependence and Its TreatmentAddiction Science & Clinical Practice, 2007
- Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brainNeuroscience, 2007
- The cannabis withdrawal syndromeCurrent Opinion in Psychiatry, 2006
- Cannabinoid tolerance and dependence: A review of studies in laboratory animalsPharmacology Biochemistry and Behavior, 2005
- Reinforcing effects of oral Δ9-THC in male marijuana smokers in a laboratory choice procedurePsychopharmacology, 2005
- Review of the Validity and Significance of Cannabis Withdrawal SyndromeAmerican Journal of Psychiatry, 2004
- Marijuana Withdrawal in Humans: Effects of Oral THC or DivalproexNeuropsychopharmacology, 2003
- Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamideBritish Journal of Pharmacology, 2001